Compare CHD & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHD | ILMN |
|---|---|---|
| Founded | 1846 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.4B | 19.4B |
| IPO Year | 2014 | 2000 |
| Metric | CHD | ILMN |
|---|---|---|
| Price | $95.80 | $129.48 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 17 | 17 |
| Target Price | $102.41 | ★ $124.24 |
| AVG Volume (30 Days) | ★ 1.7M | 1.3M |
| Earning Date | 05-01-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.29% | N/A |
| EPS Growth | 27.43 | ★ 170.87 |
| EPS | 3.02 | ★ 5.45 |
| Revenue | ★ $6,203,200,000.00 | $4,343,000,000.00 |
| Revenue This Year | $0.27 | $6.52 |
| Revenue Next Year | $3.65 | $5.60 |
| P/E Ratio | $31.43 | ★ $23.37 |
| Revenue Growth | ★ 1.57 | N/A |
| 52 Week Low | $81.33 | $69.88 |
| 52 Week High | $106.12 | $155.53 |
| Indicator | CHD | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 50.55 | 56.31 |
| Support Level | $95.28 | $127.99 |
| Resistance Level | $96.26 | $136.86 |
| Average True Range (ATR) | 2.01 | 5.14 |
| MACD | 0.37 | 0.53 |
| Stochastic Oscillator | 80.63 | 79.60 |
Church & Dwight is the leading global producer of baking soda. Its portfolio extends beyond its legacy category to include laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its brands also include Batiste, OxiClean, Vitafusion, Hero, and TheraBreath, which, together with Arm & Hammer, account for around 70% of its annual sales and profits. Most recently, the firm added Touchland and its hand sanitizer business to its fold. Even as it works to expand its product reach, Church & Dwight still derives around 80% of its sales from its home market in the US.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.